



# Pfizer Oncology ASCO 2008 Media Briefing to Discuss Study Results in Broad Range of Cancers

Thursday, May 29, 2008 - 10:44pm

--(BUSINESS WIRE)--

## WHAT:

Pfizer Oncology will host a journalist briefing at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, June 1, 2008, highlighting key data presentations from a variety of compounds in several difficult-to-treat tumor types, including renal cell carcinoma and non-small cell lung cancer. Leading oncology physicians and researchers will present study results and offer their professional perspective.

## WHO:

Robert Figlin, M.D., F.A.C.P., City of Hope

Abstract #5024: "Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)"

Antonio Gualberto, M.D., Ph.D., Pfizer Global Research and

## Development

Abstract #10501: "Safety, pharmacokinetics and preliminary activity of the anti-IGF-1R antibody CP-751,871 in sarcoma patients"

Daniel Karp, M.D., M.D. Anderson Cancer Center

Abstract #8000: "Characterization of NSCLC patients responding to anti-IGF-1R therapy"

Pasi A. Janne, M.D., Ph.D., Dana-Farber Cancer Institute

Abstract #8027, Poster #8: "Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC"

John H. Sampson, M.D., Ph.D., Duke University Medical Center

Abstract #2061: "Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM"

WHEN:

Sunday, June 1, 2008 at 6:00 PM (CT)

WHERE:

Westin River North - Grand Ballroom A&B 320 N. Dearborn Avenue Chicago, IL 60610  
(312) 744-1900

Rx Mosaic Health Jacqueline Karis 212-336-7534 347-267-9353 [jkaris@rxmosaic.com](mailto:jkaris@rxmosaic.com)